HK Stock Market Move | SINO BIOPHARM (01177) up more than 4% as the self-developed innovative drug "lofexidine" IB/IIA phase clinical trial results published in "Blood" journal.

SINO BIOPHARM(01177) rose by over 4%, rising by 4.48% to HK$3.5 as of the time of drafting, with a turnover of HK$203 million. In terms of news, on March 10, SINO BIOPHARM announced that the group's independently developed Class 1 innovative drug "Rovadicitinib" for the treatment of chronic graft-versus-host disease (cGVHD) has had its Phase Ib/IIa clinical research results published in the top international hematology journal "Blood" (IF: 21.0). Rovadicitinib is the world's first dual JAK and ROCK inhibitor with a targeted dual anti-inflammatory and anti-fibrotic mechanism. The drug has shown therapeutic potential in the treatment of cGVHD, bone marrow fibrosis, hemophagocytic syndrome, and other diseases. It is reported that JAK and ROCK are two key signaling pathways regulating immune responses and fibrosis processes. Rovadicitinib, through its innovative dual inhibitory action, simultaneously blocks abnormal immune activation and fibrosis processes, demonstrating excellent disease control rates in cGVHD patients and providing a safe and effective treatment choice for patients. This research, certified by "Blood", not only confirms the scientific value of the drug but also provides a new treatment option for cGVHD patients.